Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0S8AV
|
||||
| Former ID |
DNC007018
|
||||
| Drug Name |
SOPHORAFLAVANONE B
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528557] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H20O5
|
||||
| Canonical SMILES |
CC(=CCC1=C(C=C(C2=C1OC(CC2=O)C3=CC=C(C=C3)O)O)O)C
|
||||
| InChI |
1S/C20H20O5/c1-11(2)3-8-14-15(22)9-16(23)19-17(24)10-18(25-20(14)19)12-4-6-13(21)7-5-12/h3-7,9,18,21-23H,8,10H2,1-2H3/t18-/m0/s1
|
||||
| InChIKey |
LPEPZZAVFJPLNZ-SFHVURJKSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Estrogen receptor | Target Info | Inhibitor | [528557] | |
| Estrogen receptor beta | Target Info | Inhibitor | [528557] | ||
| CGMP-specific 3',5'-cyclic phosphodiesterase | Target Info | Inhibitor | [529676] | ||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Signaling events mediated by HDAC Class II | |||||
| Plasma membrane estrogen receptor signaling | |||||
| LKB1 signaling events | |||||
| Regulation of Telomerase | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| FOXM1 transcription factor network | |||||
| Validated nuclear estrogen receptor alpha network | |||||
| Signaling mediated by p38-alpha and p38-beta | |||||
| FOXA1 transcription factor networker_nongenomic_pathway:Plasma membrane estrogen receptor signaling | |||||
| Validated nuclear estrogen receptor beta network | |||||
| WikiPathways | Estrogen signaling pathway | ||||
| Nuclear Receptors Meta-Pathway | |||||
| Estrogen Receptor Pathway | |||||
| Signaling by ERBB4 | |||||
| JAK/STAT | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Leptin signaling pathway | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| Integrated Breast Cancer Pathway | |||||
| Nuclear ReceptorsWP706:SIDS Susceptibility Pathways | |||||
| Ovarian Infertility Genes | |||||
| Nuclear Receptors | |||||
| References | |||||
| Ref 528557 | J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta. | ||||
| Ref 529676 | J Nat Prod. 2008 Sep;71(9):1513-7. Epub 2008 Sep 9.Potent inhibition of human phosphodiesterase-5 by icariin derivatives. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.